Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin

Rheumatology

Volumn 49, Issue 3, 2009, Pages 556-562

  Floßmann, Oliver ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cyclophosphamide; Deoxyspergualin; Gusperimus; Refractory disease; Vasculitis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CHEST INFECTION; CLINICAL ARTICLE; CONDUCTION DEAFNESS; CONJUNCTIVITIS; CYTOPENIA; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EYE INFECTION; FATIGUE; FEMALE; HEARTBURN; HEMATURIA; HUMAN; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE ULCER; LEUKOCYTE COUNT; LEUKOPENIA; LONG TERM CARE; LUNG INFILTRATE; LUNG NODULE; MALE; MOUTH PAIN; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; ORBIT GRANULOMA; PERICARDITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; RESTLESS LEGS SYNDROME; RHAGADES; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SKIN DEFECT; SUBGLOTTIC STENOSIS; THRUSH; TRACHEA STENOSIS; WEGENER GRANULOMATOSIS; WEIGHT REDUCTION;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GUANIDINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 77950524962     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep411     Document Type: Article

References (23)

1. Mukhtyar C, Guillevin L, Cid MC et al. Eular recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
2. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
3. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
4. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
5. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
6. Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-9.
7. Booth AD, Almond MK, Burns A et al. Outcome of anca-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84.
8. Birck R, Warnatz K, Lorenz HM et al. 15-Deoxyspergualin in patients with refractory anca-associated systemic vas- culitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
9. Flossmann O, Baslund B, Bruchfeld A et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009;68:1125-30.
10. Schmitt WH, Birck R, Heinzel PA et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005;20:1083-92.
11. Flossmann O, Jayne DR. Maintaining remission in a patient with vasculitis. Nat Clin Pract Rheumatol 2008;4:499-504.
12. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
13. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
14. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009;68:1827-32.
15. Trotti A, Colevas AD, Setser A et al. Ctcae v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
16. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
17. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology 2001;40:492-8.
18. Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31.
19. Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-18.
20. Koukoulaki M, Jayne DR.. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006;102:c100-7.
21. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.
22. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm anti-body associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (campath-1h). Ann Rheum Dis 2008;67:1322-7.
23. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68.